257 reports of this reaction
1.8% of all TRANEXAMIC ACID reports
#11 most reported adverse reaction
FEBRILE NEUTROPENIA is the #11 most commonly reported adverse reaction for TRANEXAMIC ACID, manufactured by Pfizer Laboratories Div Pfizer Inc. There are 257 FDA adverse event reports linking TRANEXAMIC ACID to FEBRILE NEUTROPENIA. This represents approximately 1.8% of all 13,960 adverse event reports for this drug.
Patients taking TRANEXAMIC ACID who experience febrile neutropenia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
FEBRILE NEUTROPENIA is a less commonly reported adverse event for TRANEXAMIC ACID, but still significant enough to appear in the safety profile.
In addition to febrile neutropenia, the following adverse reactions have been reported for TRANEXAMIC ACID:
The following drugs have also been linked to febrile neutropenia in FDA adverse event reports:
FEBRILE NEUTROPENIA has been reported as an adverse event in 257 FDA reports for TRANEXAMIC ACID. This does not prove causation, but indicates an association observed in post-market surveillance data.
FEBRILE NEUTROPENIA accounts for approximately 1.8% of all adverse event reports for TRANEXAMIC ACID, making it a notable side effect.
If you experience febrile neutropenia while taking TRANEXAMIC ACID, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.